Annoroad Passed the “2018 International Tumor DNA (ctDNA) Gene Mutation Test EQA with Two Full Marks.
2019.08.05

Good news one by one ~ Annoroad gets two full marks! Annoroad passed the 2018 International Tumor Free DNA (ctDNA) gene mutation test EQA successfully.


1.jpg



This EQA was carried out by NCCL and RCPAQAP jointly. It is the first time that the NCCL has carried out tumor gene test EQA jointly with foreign centers. It is used to assess the ability of ctDNA gene mutation test in clinical laboratories worldwide. In this EQA, a total of 116 laboratories participated in China, of which 101 returned result, and a total of 8 quality evaluation samples were issued. The number as follows: 1801, 1802, 1803, 1804, 1805, 1806, 1807, 1808. All variant type tests (SNV, CNV, fusion) were assessed, and the percentage of mutant alleles was approximately 0.01% to 15%. The qualitative test PT results of the laboratory are as follows:


2.jpg

3.jpg


In this EQA, Annoroad uses the NGS method and the digital PCR method respectively, and the test results are both full marks. This is the perfect embodiment of Annoroad’s standard ability and accuracy during the experiment, which proves the excellent strength of Annoroad in the test of tumor ctDNA gene mutation.

Since its establishment, Annoroad has shown strong technical advantages in the fields of reproductive, oncology and other related clinical tests. Annoroad has passed the domestic and international EQA with full marks for many times, which fully demonstrates that Annoroad’s comprehensive strength in sample management, process control and quality supervision has been in the leading level of the industry. In the future, Annoroad will continue to adhere to the philosophy of “genetic technology makes life bloom”. As always, we strictly control all aspects of testing and testing, and standardize every test result with high standards and provide more scientific and accurate guarantee for clinical diagnosis and treatment.

分享:

Copyright © Annoroad Gene Technology 京ICP备12029022号-1